New Risk • Apr 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$19.6m market cap, or US$14.3m). Announcement • Feb 23
DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026 DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026. Location: british columbia, vancouver Canada Announcement • Jan 19
Diagnostear Technologies Inc. Announces Highly Encouraging Interim Results from Its Ongoing Multi-Center Israeli Clinical Study DiagnosTear Technologies Inc. announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of its TeaRxTM Red Eye diagnostic platform. TeaRxTM Red Eye is being developed as the first rapid, multi-biomarker, point-of-care diagnostic device designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis - three clinically similar but therapeutically distinct causes of red eye that together account for hundreds of millions of clinic visits worldwide each year. The lack of rapid, objective diagnostics for these conditions continues to drive misdiagnosis, inappropriate treatment, and unnecessary antibiotic and antiviral use. The Israeli clinical program was initiated in October 2023 and is being conducted across leading community and hospital sites, including two Leumit Health Services clinics in Tel-Aviv and Jerusalem, one Clalit Health Services clinic in Jerusalem, Kaplan Medical Center in Rehovot, share Zedek Medical Center in Jerusalem, and Soroka Medical Center in Beer-Sheva. The study enrolls patients presenting with suspected infectious or allergic red eye and involves collection of tear fluid samples by conjunctival swabbing.
Each sample is independently characterized using established laboratory reference methods, including qPCR testing for ocular Herpes (HSV-1 and HSV-2), qPCR and the QuickVue® Adenovirus test (QuidelOrtho), for Adenovirus, and quantitative ELISA for total tear IgE (biomarker for ocular allergy), and is tested in parallel using the TeaRxTM Red Eye assay. To date, 130 subjects have been recruited into this study. Among these, 66 samples have been evaluated for adenovirus, 60 for HSV-1/2, and 61 for total tear IgE, meeting protocol criteria for eligibility. Based on these eligible samples, TeaRxTM Red Eye has demonstrated excellent positive and negative agreement rates of 92% and 100% for Adenovirus, 100% and 100% for HSV-1/2, and 73% and 93% for total tear IgE, respectively, when compared to the independent reference methods. These interim results indicate that TeaRxTM Red Eye reliably identifies viral causes of red eye, supporting clearer point-of-care decisions and reducing unnecessary treatments. The Israeli study is expected to be completed by the second quarter of 2026. As previously reported, DiagnosTear has also initiated complementary clinical programs in India, focused on HSV, and in
France, focused on tear IgE for allergic conjunctivitis, both of which are also expected to be completed by the second quarter of 2026. Together, these studies are designed to support regulatory submissions and global commercialization of TeaRxTM Red Eye. 
